ERBB2 and triple-negative breast carcinoma: Further examination based on the molecular subtypes of tumors revealed that this difference in prognosis was mostly seen in patients with HER2-positive and hormone receptor (HR)-positive/HER2-negative (HRpos/HER2neg), and less in triple-negative breast cancer [9,15].